CD8A and myeloid sarcoma: Thus, while extending ocrelizumab dosing interval following B lymphocyte counts could be effective on the inflammatory aspects of MS (i.e., relapses, MRI lesions) [19], CD8 cytotoxic T lymphocytes progressively decrease during treatment and would very likely require regular infusions to be constantly modulated, with subsequent effect on disability progression [18].